Italy and Japan for Fermiscan
Thursday, 12 March, 2009
Japanese company Hitachi Chemical has taken an option on an exclusive licence to operate Fermiscan’s breast cancer test in Japan and Korea.
Hitachi Chemical will undertake a six-month feasibility study on the potential of the technology, which uses synchrotron light to detect breast cancer in human hair.
Fermiscan is providing the test for free at the Sydney Breast Clinic, which it owns, as part of its validation program.
The company also announced that an Italian national health service unit which has been testing the diagnostic was planning to further evaluate the test in a multi-centre study in Europe.
Last month, Fermiscan signed a commercial user agreement with the Australian Synchrotron to secure weekly beam time at the facility in advance of commercialisation of the test in the near future.
Fermiscan currently uses the synchrotron in Chicago for its test and said using the Australian Synchrotron would be significantly cheaper.
Top 6 artificial sweeteners associated with accelerated brain aging
An eight-year study tracking brain health of 12,772 Brazilian adults has associated six sugar...
1500 Queensland women to help develop ovarian cancer screening test
Postmenopausal women between the ages of 50 and 74 with intact ovaries, and no prior history of...
A neuroscientist and biochemist's antiviral lightbulb moment
While studying how certain processes work inside the human brain, an Australian scientist...
